BMO Capital Maintains Outperform on C4 Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained an 'Outperform' rating on C4 Therapeutics (NASDAQ:CCCC), but lowered the price target from $18 to $16.

November 02, 2023 | 6:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
C4 Therapeutics' price target has been lowered from $18 to $16 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100